Taysha Gene Therapies, Inc. (TSHA) Ownership
TSHA ownership summary
as of October 18, 2026- Institutions
- 94.3% of shares outstanding
- Insiders
- 9.45% of shares outstanding
- Shares outstanding
- 325.8M
- Float
- 232.6M shares available to trade
- Short interest
- 17.15% 55.0M shares short
- Days to cover
- 14.29 short interest up 7.0% vs prior month
- Institutions 94.27%
- Insiders 9.45%
TSHA top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | venBio Select Advisor LLC | 7.35% | 23.9M | $86.5M | +2.2M (+10.1%) | June 30, 2026 |
| 2 | RA Capital Management, LLC | 7.25% | 23.6M | $85.3M | — | June 30, 2026 |
| 3 | The Goldman Sachs Group Inc | 6.99% | 22.7M | $82.2M | +343,473 (+1.5%) | June 30, 2026 |
| 4 | BlackRock Inc | 6.37% | 20.7M | $74.9M | +2.3M (+12.7%) | June 30, 2026 |
| 5 | Vestal Point Capital LP | 5.98% | 19.4M | $70.3M | +1.4M (+7.9%) | June 30, 2026 |
| 6 | Morgan Stanley - Brokerage Accounts | 5.08% | 16.5M | $59.7M | −1.5M (−8.2%) | June 30, 2026 |
| 7 | RTW INVESTMENTS, LLC | 4.17% | 13.6M | $49.1M | −119,990 (−0.9%) | June 30, 2026 |
| 8 | FMR Inc | 4.11% | 13.3M | $48.3M | −984,842 (−6.9%) | June 30, 2026 |
| 9 | Vanguard Capital Management, LLC | 3.84% | 12.5M | $45.2M | +2.2M (+22.0%) | June 30, 2026 |
| 10 | State Street Corp | 3.52% | 11.4M | $41.3M | +212,842 (+1.9%) | June 30, 2026 |
| 11 | Siren, L.L.C. | 3.03% | 9.8M | $35.6M | +1.0M (+11.5%) | June 30, 2026 |
| 12 | Octagon Capital Advisors LP | 2.98% | 9.7M | $35.1M | +833,333 (+9.4%) | June 30, 2026 |
| 13 | Geode Capital Management, LLC | 2.02% | 6.6M | $23.7M | +1.0M (+18.6%) | June 30, 2026 |
| 14 | Polar Capital Holdings PLC | 1.58% | 5.1M | $18.5M | −537,207 (−9.5%) | June 30, 2026 |
| 15 | MPM Oncology Impact Management LP | 1.39% | 4.5M | $16.3M | +4.5M (0.0%) | June 30, 2026 |
| 16 | D. E. Shaw & Co LP | 1.35% | 4.4M | $15.9M | −28,649 (−0.6%) | June 30, 2026 |
| 17 | Baker Bros Advisors LP | 1.23% | 4.0M | $14.5M | — | June 30, 2026 |
| 18 | Wellington Management Company LLP | 1.22% | 4.0M | $14.4M | +3.3M (+534.7%) | June 30, 2026 |
| 19 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 1.20% | 3.9M | $14.1M | +1.0M (+34.8%) | June 30, 2026 |
| 20 | Casdin Capital, LLC | 1.00% | 3.2M | $11.8M | — | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 12 holders added 20.5M shares and 5 cut 3.1M.
TSHA top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.82% | 9.2M | $33.2M | −16,667 (−0.2%) | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 2.12% | 6.9M | $25.0M | −79,488 (−1.1%) | September 30, 2026 |
| 3 | State Street® SPDR® S&P® Biotech ETF | 1.59% | 5.2M | $18.7M | −98,850 (−1.9%) | September 30, 2026 |
| 4 | Polar Capital Biotech S Inc | 1.49% | 4.8M | $17.5M | — | August 31, 2026 |
| 5 | Fidelity Growth Company Fund | 1.28% | 4.2M | $15.1M | — | August 31, 2026 |
| 6 | Fidelity Small Cap Index | 0.81% | 2.6M | $9.5M | +22,248 (+0.9%) | July 31, 2026 |
| 7 | iShares Russell 2000 Growth ETF | 0.77% | 2.5M | $9.0M | −3,158 (−0.1%) | September 30, 2026 |
| 8 | RTW Biotech Opportunities Ord | 0.74% | 2.4M | $8.7M | −5.4M (−69.2%) | December 31, 2025 |
| 9 | iShares Biotechnology ETF | 0.63% | 2.1M | $7.5M | −15,624 (−0.8%) | September 30, 2026 |
| 10 | abrdn Life Sciences Investors | 0.58% | 1.9M | $6.8M | — | August 31, 2026 |
| 11 | Pictet-Biotech P USD | 0.48% | 1.6M | $5.7M | +1.6M (0.0%) | June 30, 2026 |
| 12 | Schwab US Small-Cap ETF™ | 0.45% | 1.4M | $5.2M | +972 (+0.1%) | September 30, 2026 |
| 13 | Vanguard Russell 2000 ETF | 0.42% | 1.4M | $5.0M | +32,845 (+2.4%) | August 31, 2026 |
| 14 | Fidelity Extended Market Index | 0.40% | 1.3M | $4.7M | −10,106 (−0.8%) | August 31, 2026 |
| 15 | Fidelity Growth Company K6 | 0.34% | 1.1M | $4.0M | — | August 31, 2026 |
| 16 | Fidelity Enhanced Small Cap Core ETF | 0.33% | 1.1M | $3.9M | +2,271 (+0.2%) | September 30, 2026 |
| 17 | abrdn Healthcare Investors | 0.33% | 1.1M | $3.9M | — | August 31, 2026 |
| 18 | Fidelity Select Biotechnology | 0.29% | 940K | $3.4M | — | August 31, 2026 |
| 19 | First Trust Small Cap Gr AlphaDEX® ETF | 0.26% | 832K | $3.0M | +1,469 (+0.2%) | September 30, 2026 |
| 20 | MEDICAL BioHealth EUR Acc | 0.23% | 749K | $2.7M | +159 (+0.0%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
TSHA insider transactions
latest 13| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-10 | Sukumar Nagendran | Sell | $4.46 | 200,000 | $892,000 |
| 2026-02-04 | Kamran Alam | Sell | $4.52 | 1,655 | $7,481 |
| 2026-01-26 | Kamran Alam | Sell | $4.61 | 23,849 | $109,944 |
| 2026-01-26 | Sean P Nolan | Sell | $4.61 | 41,312 | $190,448 |
| 2026-01-26 | Sukumar Nagendran | Sell | $4.61 | 26,918 | $124,092 |
| 2026-01-23 | Kamran Alam | Sell | $4.75 | 78,968 | $375,098 |
| 2026-01-23 | Sean P Nolan | Sell | $4.75 | 136,789 | $649,748 |
| 2026-01-23 | Sukumar Nagendran | Sell | $4.75 | 89,132 | $423,377 |
| 2026-01-12 | Sukumar Nagendran | Sell | $4.71 | 200,000 | $942,000 |
| 2025-12-01 | Sukumar Nagendran | Sell | $4.51 | 260,047 | $1.2M |
| 2025-11-28 | Sukumar Nagendran | Sell | $4.75 | 110,125 | $523,094 |
| 2025-09-10 | Sukumar Nagendran | Sell | $3.23 | 200,000 | $646,000 |
| 2025-05-30 | Paul B Manning | Buy | $2.75 | 750,000 | $2.1M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
TSHA shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns TSHA
Institutional investors own 94.3% of Taysha Gene Therapies's shares and insiders 9.45%. The largest holder is venBio Select Advisor LLC with 7.35% of the shares (23.9M), as of June 30, 2026. Among the top 20 institutions, 12 added shares and 5 reduced their stake in the latest filings. Short interest is 17.15% of the float, or 14.29 days of average trading volume. The share count rose 2,007.5% since 2019.
Related: TSHA analyst forecast, TSHA key metrics. See the TSHA stock overview for the latest quote and news.
TSHA ownership FAQ
Who owns the most Taysha Gene Therapies stock?
The largest shareholders of Taysha Gene Therapies are venBio Select Advisor LLC (7.35%), RA Capital Management, LLC (7.25%), The Goldman Sachs Group Inc (6.99%), BlackRock Inc (6.37%), Vestal Point Capital LP (5.98%).
What percentage of Taysha Gene Therapies is owned by institutions?
Institutions hold 94.3% of Taysha Gene Therapies's shares outstanding; insiders hold 9.45%.
Which funds own Taysha Gene Therapies?
The largest fund holders of Taysha Gene Therapies are Vanguard MStar Total Stk Mkt Idx Invest (2.82%), iShares Russell 2000 ETF (2.12%), State Street® SPDR® S&P® Biotech ETF (1.59%), Polar Capital Biotech S Inc (1.49%), Fidelity Growth Company Fund (1.28%).
What is Taysha Gene Therapies's short interest?
55.0M shares of Taysha Gene Therapies were sold short, 17.15% of the float; at the average daily volume it would take 14.29 days to cover.
Are insiders buying or selling Taysha Gene Therapies?
Of the latest 13 reported insider transactions in Taysha Gene Therapies (since May 30, 2025), 1 were purchases and 12 were sales.
How many shares of Taysha Gene Therapies are outstanding?
Taysha Gene Therapies has 325.8M shares outstanding, of which 232.6M are in the public float.